Navigation Links
Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
Date:10/18/2007

lion and $2.74, respectively, compared with $3,377.3 million and $2.48, respectively, for the 2006 first nine months.

The increase in net income and diluted earnings per share for the 2007 first nine months, before certain significant items, resulted from higher net revenue, lower selling, general and administrative expenses, as a percentage of net revenue, higher interest income, net and higher other income, net offset, in part, by higher cost of goods sold, as a percentage of net revenue, higher research and development spending and increased income taxes. Included in other income, net were pre-tax gains from product divestitures of $60.3 million and $38.7 million for the 2007 and 2006 first nine months, respectively.

Productivity Initiatives

The Company continues with its long-term productivity initiatives, which were launched in 2005 to adapt to the changing pharmaceutical industry environment. The Company recorded charges of $117.1 million ($86.0 million after-tax or $0.06 per share-diluted) for the 2007 third quarter and $209.5 million ($152.5 million after-tax or $0.11 per share-diluted) for the 2007 first nine months. These charges include costs pertaining to the closure of a manufacturing facility owned by Amgen Inc. and used in the production of Enbrel. The closure of the manufacturing facility is expected to be completed in the fourth quarter. The 2006 third quarter and first nine months included productivity initiatives charges of $80.2 million ($54.9 million after-tax or $0.04 per share-diluted) and $154.8 million ($106.4 million after-tax or $0.08 per share-diluted), respectively.

To assist in performing third quarter and first nine months comparisons, a pro forma presentation, which excludes our productivity initiatives and favorable income tax adjustment, is provided under "Results of Operations - As Adjusted" at the end of this press release.

Share Repurchase Program

As previously announced, on September 27, 2007,
'/>"/>

SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Wyeth Launches Vaccine for Pneumococcal Disease in India
2. Wyeth Embroiled in a Lawsuit over its Hormone Replacement Therapy
3. Wyeth Pharma Wins Law Suit
4. Verdict Against Wyeth Pharma in Prempro Case
5. FDA Approves Wyeths Oral Contraceptive Lybrel
6. Autopsy reports could be valuable and informative
7. China reports declining number of SARS Cases
8. Russia Reports First SARS Case
9. Research reports that c-section deliveries are rising
10. Jharkhand reports 13,000 Malaria cases
11. Uganda Reports Failure To Contain Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Centre for Accident Research & Road Safety - Queensland ... in Transport Conference (OSIT) which is being held on ... Blackman, a CARRS-Q road safety researcher, said speed limit ... limits and related traffic controls remained in place at ... If people are asked to slow down at roadwork ...
(Date:9/19/2014)... Lifeinsure.biz has released a new ... can be purchased without medical examinations. , Life ... a life insurance policy more advantageous. Clients can read ... extra options available for a no medical exam life ... required is simple to purchase, however it is more ...
(Date:9/19/2014)... 19, 2014 Outsourcing services provider Profit By ... US IT conglomerate to provide HR outsourcing services in India. ... an exclusive partner and will act as a talent acquisition ... deploy over 120 personnel across 3 locations in India in ... , "This is a significant win for us and we ...
(Date:9/19/2014)... 2014 Kyrgyzstan has one of ... To reduce the burden of tuberculosis (TB) and ... Kyrgyz Republic, Abt Associates has been awarded the ... Program under a five-year cooperative agreement with total ... support universal and equitable access to high-quality TB ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:New Project Aims to Reduce Burden of Tuberculosis in the Kyrgyz Republic 2Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2
... disease, rheumatoid arthritis (RA) is characterized by persistent inflammation ... Beyond loss of mobility, sufferers face a high risk ... contributing to the development of RA, tumor necrosis factor ... Inhibition of TNFa has opened promising new treatment ...
... DALLAS Feb. 28, 2008 UT Southwestern Medical ... operation requiring only a single incision in the bellybutton ... It is the first such operation in North Texas. ... Homero Rivas, assistant professor of surgery, who completed the ...
... Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug Administration., The four products ... equivalent of,Bontril(R) tablets by Valeant Pharmaceuticals, are indicated ... of Phendimetrazine tartrate tablets,had annual sales of US$3.1 ...
... 40.6%, ETHEX Revenue Up 57.8% for Third Quarter, Up ... Revenue Up 16.6% for Third Quarter, Up 15.2% ... KV Pharmaceutical Company,(NYSE: KVa/KVb) today reported preliminary financial results ... 2008 ended December 31, 2007. The,results reflected continued acceleration ...
... the Robert Wood Johnson Foundation, has launched the Network for ... study health care disparities affecting minorities with chronic diseases. ... a new generation of researchers with an expertise in health ... to be directed by Dr. Michael Rodrguez, associate professor of ...
... drop in a severe form of the disorder, , , WEDNESDAY, Feb. ... decreasing, and a more severe form of the disease caused by ... Those are the two main findings from a Massachusetts study that ... and 35 babies a year before 2003 to less than 20 ...
Cached Medicine News:Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 2Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 3Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 2Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 3Health News:Actavis Extends Portfolio With Four New Products in the U.S. 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 3Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 4Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 5Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 6Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 7Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 8Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 9Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 10Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 11Health News:UCLA launches network to study health care disparities affecting minorities 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 3
(Date:9/18/2014)... Sept. 18, 2014  Low T Center endorses ... in Hyattsville, Maryland earlier ... the proper patient population for testosterone therapy (TRT), ... associated with TRT. Examining recent claims from studies that ... "available epidemiological studies do not provide convincing evidence ...
(Date:9/18/2014)... 18, 2014   MacPractice,s MacPractice MD MU ... EHR certification, which designates that the software is capable ... and Stage 2 Meaningful Use measures required to qualify ... (ARRA).  MacPractice MD MU version 5.0 was certified on ... Office of the National Coordinator-Authorized Certification Body (ONC-ACB) and ...
(Date:9/18/2014)... 2014 This BCC Research report discusses the medical device ... growth and size, and opportunities for different devices and regions. ... Patent analysis in the report focuses on technological trends in ... Europe and Japan . ... the global medical device technologies market. - Analyze market structure, ...
Breaking Medicine Technology:Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4
... , , , , NASHVILLE, Tenn. and ... find that 70 percent of surveyed pharmacy directors expect to ... of chronic pain. Tanezumab, which is expected to be the ... under medical supervision, will likely be covered as a medical ...
... , , , SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. ... ), Eli Lilly and Company (NYSE: LLY ) ... results from a head-to-head study comparing exenatide once weekly, an ... in patients with type 2 diabetes. After 24 weeks of ...
Cached Medicine Technology:Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 2Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: